University of Oxford and Serum Institute of India (SII) Partner to Develop R78C Malaria Vaccine

Key facts

• The University of Oxford and Serum Institute of India (SII) have signed a licence agreement to develop and manufacture a multi-stage malaria vaccine candidate called R78C.
• The R78C vaccine candidate is based on two Plasmodium falciparum blood-stage antigens, RIPR and CyPRA.
• SII, a Cyrus Poonawalla group company, will support the continued development, large-scale manufacture, and potential future commercialisation of the vaccine.
• The collaboration aims to provide affordable and equitable access to the vaccine for endemic regions and low and middle-income countries.
• SII has entered into a related agreement with ExpreS2ion to access its proprietary ExpreS2 expression platform for the clinical-stage production of R78C and RH5.1 vaccine components.